Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40454 KULR TECHNOLOGY GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 81-1004273 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-42431 ZSPACE, INC. (Exact name of registrant as specified in its charter) | Delaware | 35-2284050 | | --- | -- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-40493 ATAI Life Sciences N.V. (Exact name of registrant as specified in its charter) The Netherlands Not App ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39445 MSP Recovery, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 84-4117825 (State or other jurisdiction ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39445 MSP Recovery, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 84-4117825 (State or other jurisdiction ...

[Highlights](index=1&type=section&id=Highlights) ICMB reported a NAV of $5.27 per share, $0.08 million net investment income, and declared a $0.14 per share total distribution Key Financial Metrics | Metric | Value (in millions) | | :--- | :--- | | Total assets | $224.1 million | | Investment portfolio, at fair value | $204.1 million | | Net assets | $76.0 million | | Net asset value per share | $5.27 | | Weighted average yield on debt investments | 10.57% | | Net investment income before taxes (NII) | $0.8 million | | NII per share | $0.06 | | Net decrease in net assets from operations | (\$0.4) million | | Net decrease in net assets from operations per share | (\$0.03) | | Distributions paid per common share | $0.12 | - The Board of Directors declared a regular quarterly distribution of **$0.12** per share and a supplemental distribution of **$0.02** per share for the quarter ending September 30, 2025[4](index=4&type=chunk) - Net asset value (NAV) per share decreased by **$0.15** to **$5.27** as of June 30, 2025, compared to **$5.42** as of March 31, 2025[4](index=4&type=chunk) - During the quarter, ICMB invested **$19.0 million** and fully realized investments in three portfolio companies, generating an internal rate of return (IRR) of **32.82%** on these exits[4](index=4&type=chunk) - The weighted average yield on debt investments decreased slightly to **10.57%** from **10.95%** in the previous quarter[4](index=4&type=chunk) [Financial and Operational Performance](index=2&type=section&id=Financial%20and%20Operational%20Performance) The company declared a $0.14 per share distribution, invested $19.0 million, and maintained a portfolio primarily in first lien and floating rate debt [Distributions](index=2&type=section&id=Distributions) - The Board declared a distribution of **$0.12** per share for the quarter ending September 30, 2025, plus a supplemental distribution of **$0.02** per share, both payable on October 9, 2025[7](index=7&type=chunk) - This total distribution represents a **20.07%** yield on the company's share price as of June 30, 2025 The company does not expect the distribution to be comprised of a return of capital[8](index=8&type=chunk) [Portfolio and Investment Activities](index=2&type=section&id=Portfolio%20and%20Investment%20Activities) - Invested a total of **$19.0 million** in one new and four existing portfolio companies during the quarter, with new debt investments made at a weighted average yield of **9.03%**[9](index=9&type=chunk) - Received **$10.0 million** in proceeds from repayments, sales, and amortization, primarily from the realization of three investments[10](index=10&type=chunk) - Net realized and unrealized losses resulted in a decrease in net investments of approximately **$1.0 million**, or **$0.07** per share[11](index=11&type=chunk) - As of June 30, 2025, the portfolio consisted of investments in **43** companies, with **79.23%** in first lien investments and **98.50%** of the debt portfolio in floating rate investments[12](index=12&type=chunk) [Capital Resources](index=2&type=section&id=Capital%20Resources) - As of June 30, 2025, the Company had **$17.3 million** in cash (**$14.4 million** restricted) and **$29.5 million** of unused capacity under its revolving credit facility[13](index=13&type=chunk) [Subsequent Events and Corporate Actions](index=2&type=section&id=Subsequent%20Events%20and%20Corporate%20Actions) Post-quarter, the company invested an additional $0.2 million, declared a Q3 2025 distribution, and authorized a new $5 million share repurchase program - Between June 30, 2025, and August 13, 2025, the Company invested an additional **$0.2 million** in two existing portfolio companies[14](index=14&type=chunk) - On August 7, 2025, the Board authorized a new share repurchase program of up to **$5 million**, effective for one year until August 7, 2026[16](index=16&type=chunk) [Consolidated Financial Statements](index=4&type=section&id=Consolidated%20Financial%20Statements) The consolidated statements detail total assets of $224.1 million, net assets of $76.0 million, and a net decrease in assets from operations of (\$0.4) million [Consolidated Statements of Assets and Liabilities](index=4&type=section&id=Consolidated%20Statements%20of%20Assets%20and%20Liabilities) Consolidated Assets and Liabilities | (in thousands) | June 30, 2025 (Unaudited) (in thousands) | December 31, 2024 (in thousands) | | :--- | :--- | :--- | | Total investments, at fair value | $204,131 | $191,617 | | Total Assets | $224,065 | $206,852 | | Debt, net | $134,385 | $122,042 | | Total Liabilities | $148,080 | $129,250 | | Total Net Assets | $75,984 | $77,602 | | Net Asset Value Per Share | $5.27 | $5.39 | [Consolidated Statements of Operations](index=5&type=section&id=Consolidated%20Statements%20of%20Operations) Consolidated Operations Summary | For the three months ended June 30, | 2025 (in thousands) | 2024 (in thousands) | | :--- | :--- | :--- | | Total investment income | $4,545,199 | $5,119,319 | | Net expenses | $3,711,141 | $3,864,957 | | Net investment income after taxes | $604,148 | $1,309,102 | | Net realized and unrealized gain/(loss) | (\$1,038,446) | (\$3,261,248) | | Net increase (decrease) in net assets from operations | (\$434,298) | (\$1,952,146) | | Earnings per share (Basic and diluted) | (\$0.03) | (\$0.14) | [Company Overview and Disclosures](index=6&type=section&id=Company%20Overview%20and%20Disclosures) The company is an externally managed BDC focused on middle-market investments, with the report including standard forward-looking statement disclaimers - The Company is an externally managed BDC with an investment objective to maximize total return via current income and capital appreciation from debt and equity investments in middle-market companies[19](index=19&type=chunk) - The report contains forward-looking statements that are based on current expectations and are subject to substantial risks and uncertainties, and actual results may differ materially[20](index=20&type=chunk)[21](index=21&type=chunk)

[PART I. FINANCIAL INFORMATION](index=4&type=section&id=PART%20I.%20FINANCIAL%20INFORMATION) [Item 1. Financial Statements](index=4&type=section&id=Item%201.%20Financial%20Statements) This section presents unaudited condensed consolidated financial statements, detailing financial position, performance, and cash flows, with a going concern warning [Condensed Consolidated Balance Sheets](index=4&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) The balance sheet shows decreased cash, stable total assets, reduced liabilities, and increased stockholders' equity as of June 30, 2025 Condensed Consolidated Balance Sheet Highlights (in thousands) | Balance Sheet Item | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Cash and cash equivalents | $3,562 | $9,173 | | Total current assets | $42,662 | $39,489 | | Total assets | $76,010 | $76,670 | | Convertible debentures payable (current) | $11,762 | $20,362 | | Total current liabilities | $24,178 | $37,344 | | Total liabilities | $30,636 | $41,295 | | Accumulated deficit | $(703,184) | $(693,225) | | Total stockholders' equity | $45,374 | $35,375 | [Condensed Consolidated Statements of Operations](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) The statements show significantly lower net losses for Q2 and H1 2025 due to reduced operating expenses, despite decreased revenue Statement of Operations Summary (in thousands) | Metric | Q2 2025 | Q2 2024 | 6 Months 2025 | 6 Months 2024 | | :--- | :--- | :--- | :--- | :--- | | Total Revenue | $6,733 | $7,771 | $13,190 | $16,540 | | Loss from Operations | $(7,800) | $(17,018) | $(16,262) | $(48,139) | | Net Loss | $(6,857) | $(16,224) | $(9,958) | $(47,646) | | Net Loss Per Share | $(1.99) | $(14.41) | $(3.24) | $(47.50) | [Condensed Consolidated Statements of Cash Flows](index=8&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Cash flow statements show significantly reduced cash used in operations, with financing activities providing capital, resulting in a net cash decrease Cash Flow Summary for Six Months Ended June 30 (in thousands) | Cash Flow Activity | 2025 | 2024 | | :--- | :--- | :--- | | Net cash used in operating activities | $(6,251) | $(49,109) | | Net cash (used in)/provided by investing activities | $(12,087) | $76,217 | | Net cash provided by/(used in) financing activities | $12,360 | $(23,596) | | Net (decrease)/increase in cash | $(6,011) | $3,485 | | Cash, cash equivalents and restricted cash at end of period | $3,562 | $21,833 | [Notes to Condensed Consolidated Financial Statements](index=10&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) Notes provide critical context, including a going concern warning due to recurring losses, and detail accounting policies, debt, and equity changes - The company effected a 1-for-60 reverse stock split on January 24, 2025. All share and per-share amounts have been retroactively adjusted[25](index=25&type=chunk) - Management has substantial doubt about the company's ability to continue as a going concern within 12 months, citing recurring net losses, negative cash flows, and the need to raise additional funding[28](index=28&type=chunk)[30](index=30&type=chunk) - As of June 30, 2025, the company had **$12.1 million** of principal outstanding under its Debentures and an accumulated deficit of **$703.2 million**[29](index=29&type=chunk) Revenue by Source - Six Months Ended June 30 (in thousands) | Revenue Source | 2025 | 2024 | | :--- | :--- | :--- | | Instruments | $2,088 | $3,874 | | Consumables | $6,523 | $6,033 | | Software | $3,703 | $3,431 | | **Total product revenue** | **$12,314** | **$13,338** | | Service and other | $876 | $3,202 | | **Total revenue** | **$13,190** | **$16,540** | [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=31&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses decreased revenue but improved net loss due to cost cuts, emphasizing a strategic shift and reiterating substantial doubt about going concern [Overview and Recent Highlights](index=31&type=section&id=Overview%20and%20Recent%20Highlights) The company's OGM system installed base grew, flowcell sales increased, but it faces slowdowns in the Asia Pacific region - The installed base of OGM systems grew to **378** as of June 30, 2025, up **4%** from 363 a year prior[124](index=124&type=chunk) - Flowcell sales increased by approximately **17%** to **7,233 units** in Q2 2025 compared to 6,165 in Q2 2024[124](index=124&type=chunk) - The company is experiencing a slowdown in its Asia Pacific business due to regional headwinds and reliance on government funding by manufacturing partners[125](index=125&type=chunk) [Results of Operations](index=34&type=section&id=Results%20of%20Operations) Results show declining revenue but significantly improved profitability for Q2 and H1 2025, driven by substantial operating expense reductions Comparison of Three Months Ended June 30 (in thousands) | Metric | 2025 | 2024 | Change ($) | Change (%) | | :--- | :--- | :--- | :--- | :--- | | Total Revenue | $6,733 | $7,771 | $(1,038) | (13)% | | Gross Profit | $3,477 | $2,585 | $892 | 35% | | Loss from Operations | $(7,800) | $(17,018) | $9,218 | (54)% | | Net Loss | $(6,857) | $(16,224) | $9,367 | (58)% | - The decrease in Q2 revenue was driven by a **38% drop** in instrument sales and a **66% drop** in service revenue, partially offset by a **28% increase** in consumables sales[138](index=138&type=chunk)[139](index=139&type=chunk) - Operating expenses in Q2 2025 decreased by **42%** year-over-year, primarily due to headcount reductions and other cost-saving initiatives announced in 2023 and 2024[137](index=137&type=chunk)[144](index=144&type=chunk)[145](index=145&type=chunk) [Liquidity and Capital Resources](index=39&type=section&id=Liquidity%20and%20Capital%20Resources) The company faces critical liquidity issues and substantial doubt about its going concern, requiring additional capital in the near term - As of June 30, 2025, the company had **$3.6 million** in cash and cash equivalents, **$12.9 million** in short-term investments, and an accumulated deficit of **$703.2 million**[164](index=164&type=chunk) - Management has determined there is substantial doubt about the company's ability to continue as a going concern, as available cash is not sufficient to operate for the next twelve months[176](index=176&type=chunk) - Based on current plans, the company believes it can fund operations into the first quarter of 2026, but will require additional capital in the very near term to continue[174](index=174&type=chunk) - In the first half of 2025, the company raised approximately **$16.4 million** in gross proceeds from sales of common stock and warrants through its ATM facilities and other offerings[182](index=182&type=chunk) [Item 3. Quantitative and Qualitative Disclosures about Market Risk](index=44&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20about%20Market%20Risk) The company is not required to provide this information as it qualifies as a smaller reporting company - As a smaller reporting company, Bionano Genomics is not required to provide the information for this item[192](index=192&type=chunk) [Item 4. Controls and Procedures](index=44&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded disclosure controls and procedures were effective, with no material changes in internal control over financial reporting - Management concluded that the company's disclosure controls and procedures were effective as of the end of the period covered by the report (June 30, 2025)[195](index=195&type=chunk) - No changes in internal control over financial reporting occurred during the quarter that have materially affected, or are reasonably likely to materially affect, internal controls[196](index=196&type=chunk) [PART II. OTHER INFORMATION](index=46&type=section&id=PART%20II.%20OTHER%20INFORMATION) [Item 1. Legal Proceedings](index=46&type=section&id=Item%201.%20Legal%20Proceedings) The company reports no material legal proceedings - The company reports no material legal proceedings[198](index=198&type=chunk) [Item 1A. Risk Factors](index=46&type=section&id=Item%201A.%20Risk%20Factors) This section details significant risks, including financial viability, operational challenges, regulatory hurdles, intellectual property, and stock price volatility [Risks related to our financial condition and need for additional capital](index=49&type=section&id=Risks%20related%20to%20our%20financial%20condition%20and%20need%20for%20additional%20capital) The company faces substantial doubt about its going concern due to recurring losses, requiring immediate capital to avoid curtailing operations - The company has incurred recurring net losses since inception and expects losses to continue, with an accumulated deficit of **$703.2 million** as of June 30, 2025[203](index=203&type=chunk) - There is substantial doubt about the company's ability to continue as a going concern, and without raising sufficient additional capital in the very near term, it may be required to curtail, liquidate, or cease operations entirely[204](index=204&type=chunk) - The company's ability to raise capital may be limited by SEC rules, as its public float is less than **$75.0 million**, restricting the use of its Form S-3 shelf registration statement[206](index=206&type=chunk) [Risks related to our business operations](index=58&type=section&id=Risks%20related%20to%20our%20business%20operations) Operational risks include acquisition integration, market acceptance, supply chain reliance, lengthy sales cycles, and international and data security challenges - Acquisitions could disrupt business, and the company may not achieve the expected revenues or synergies, as exemplified by the full impairment of goodwill and intangible assets from the Purigen and Lineagen acquisitions[243](index=243&type=chunk)[250](index=250&type=chunk) - The company relies on a single contract manufacturer for its OGM systems and a limited number for its chip consumables, creating significant supply chain risk[285](index=285&type=chunk) - The company's products are currently for Research Use Only (RUO), and any move toward clinical diagnostic use would require expensive and uncertain regulatory clearance from the FDA[280](index=280&type=chunk) [Risks related to government regulation and diagnostic product reimbursement](index=72&type=section&id=Risks%20related%20to%20government%20regulation%20and%20diagnostic%20product%20reimbursement) Significant regulatory risks include FDA changes to LDTs, complex billing and reimbursement, and compliance with federal and state healthcare laws - A significant change in how the FDA regulates Laboratory Developed Tests (LDTs), which Bionano Laboratories provides, could materially harm the business[338](index=338&type=chunk) - Billing for diagnostic testing is complex and subject to risks of non-payment, audits, and recoupment from payors, which could negatively affect revenue and cash flow[343](index=343&type=chunk)[347](index=347&type=chunk) - The business is subject to numerous federal and state healthcare laws, including anti-kickback statutes and false claims laws, and non-compliance could result in substantial penalties[368](index=368&type=chunk) [Risks related to intellectual property](index=79&type=section&id=Risks%20related%20to%20intellectual%20property) Intellectual property risks include inadequate patent protection, potential challenges to existing patents, and costly infringement claims from third parties - The company relies on a global patent portfolio of over **135 issued patents**, but cannot guarantee that pending applications will issue or that existing patents will not be challenged or invalidated[378](index=378&type=chunk)[379](index=379&type=chunk) - Some of the company's intellectual property was developed with U.S. government funding and is subject to federal regulations, including "march-in" rights, which could limit exclusive rights[385](index=385&type=chunk) - The company may be subject to costly litigation if sued for infringing on the intellectual property rights of third parties, which could result in injunctions or substantial damage awards[391](index=391&type=chunk)[393](index=393&type=chunk) [Risks related to ownership of our securities](index=86&type=section&id=Risks%20related%20to%20ownership%20of%20our%20securities) Risks for investors include high stock price volatility, potential failure of reverse stock splits, and anti-takeover provisions - The company's stock price has been and is expected to remain highly volatile, which could lead to significant investment losses[421](index=421&type=chunk)[422](index=422&type=chunk) - The company has implemented multiple reverse stock splits to maintain its Nasdaq listing but cannot guarantee it will continue to meet the minimum bid price or other listing requirements[428](index=428&type=chunk)[429](index=429&type=chunk)[433](index=433&type=chunk) - Anti-takeover provisions in the company's charter documents and Delaware law could delay or prevent a change of control, potentially limiting the market price of its securities[446](index=446&type=chunk) [Risks Related to Our Review of Strategic Alternatives](index=91&type=section&id=Risks%20Related%20to%20Our%20Review%20of%20Strategic%20Alternatives) Review of strategic alternatives offers no assurance of a transaction, potentially leading to dissolution and significant stockholder loss - The company is evaluating strategic alternatives, but there is no guarantee that any transaction will be pursued or successfully consummated[453](index=453&type=chunk) - The process of evaluating strategic alternatives is costly and time-consuming, and may divert management's attention from the business[455](index=455&type=chunk) - If a strategic transaction is not completed, the board may decide to pursue dissolution and liquidation, where the cash available for distribution to stockholders would be uncertain and could be minimal[460](index=460&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=94&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company reports no unregistered sales of equity securities during the period - None reported[466](index=466&type=chunk) [Item 3. Defaults Upon Senior Securities](index=94&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) The company reports no defaults upon senior securities - None reported[467](index=467&type=chunk) [Item 4. Mine Safety Disclosures](index=94&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is not applicable to the company - Not applicable[468](index=468&type=chunk) [Item 5. Other Information](index=94&type=section&id=Item%205.%20Other%20Information) No director or officer adopted, terminated, or modified a Rule 10b5-1 trading arrangement during the quarter - No director or officer of the Company adopted, terminated or modified a Rule 10b5-1 trading arrangement during the three months ended June 30, 2025[469](index=469&type=chunk) [Item 6. Exhibits](index=95&type=section&id=Item%206.%20Exhibits) This section lists exhibits filed with the Form 10-Q, including corporate governance documents, securities forms, and certifications

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34375 PLUS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) DELAWARE 33-0827593 (State or other jurisdic ...

Exhibit 99.1 Tyra Biosciences Reports Second Quarter 2025 Financial Results and Highlights - Dosed first patient in SURF302 for intermediate risk non-muscle invasive bladder cancer (IR NMIBC) - - Cash, cash equivalents, and marketable securities of $296.3 million at Q2 2025; runway through at least 2027 - • Dabogratinib (formerly TYRA-300) is an oral investigational FGFR3-selective inhibitor being developed for the treatment of IR NMIBC and ACH. o Dosed first patient in Phase 2 NMIBC Study – SURF302. SURF30 ...

Exhibit 99.1 Jefferson Capital Reports Second Quarter 2025 Results 47% Growth in Revenue to $152.7 Million Collections Grow 85% to $255.7 Million with Estimated Remaining Collections ("ERC") up 31% to a Record $2.9 Billion Pre-tax Income up 82% to $62.0 Million with Net Income up 48% to $47.7 Million Adjusted Pre-tax Income up 55% to $61.7 Million Board of Directors Declares Quarterly Cash Dividend of $0.24 per Share MINNEAPOLIS, August 14, 2025 /GLOBE NEWSWIRE/ -- Jefferson Capital, Inc. ("Jefferson Capita ...